GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Cash Receipts from Loans

Canbridge Pharmaceuticals (HKSE:01228) Cash Receipts from Loans


View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals Cash Receipts from Loans?

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.

Canbridge Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Cash Receipts from Loans
Comparable Companies
HKSE:08158 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269 INSM HKSE:01801 SHSE:603392
Traded in Other Exchanges
N/A
Address
No. 388 Xinping Street, Unit 18, 6th Floor, Building 21, Suzhou Industrial Park, Pilot Free Trade Zone, Jiangsu Province, Suzhou, CHN
Website
https://www.canbridgepharma.com
Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. Its differentiated drug portfolio comprises both approved drugs and a pipeline of assets, targeting prevalent rare disease indications that have unmet needs and market potential. The group's approved products include Hunterase (CAN101) for the treatment of MPS II and Livmarli for the treatment of ALGS. The various other drug candidates in its development pipeline include CAN 103, CAN 107, CAN 104, CAN 105, and CAN 204, spanning biologics, small molecules, and gene therapy, targeting prevalent rare diseases and oncology indications. Geographically, it derives revenue from Chinese Mainland and other regions.
Executives
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Xue James Qun 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Athos Capital Limited 2102 Investment manager
Moskey Matthew Love 2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela 2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund 2101 Beneficial owner
Ctx Pharma Holdings Limited 2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Kolchinsky Peter 2305 Beneficiary of a trust
Ra Capital Management, L.p. 2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner